What is OSSIO?
OSSIO specializes in the development of innovative bone healing solutions that eliminate the need for permanent metal hardware. Its flagship OSSIOfiber technology utilizes natural minerals found in human bone to create implants—such as suture anchors and fixation nails—that provide superior structural integrity while facilitating natural bone regeneration. By offering a bio-integrative alternative to traditional metallic implants, OSSIO addresses critical unmet needs in the orthopedic sector, significantly improving patient recovery outcomes and reducing long-term complications. The company's market position is defined by its commitment to advancing medical standards through material science, effectively bridging the gap between temporary fixation and permanent biological integration.
How much funding has OSSIO raised?
OSSIO has raised a total of $138.1M across 4 funding rounds:
Series A
$22M
Series C
$38.5M
Private Equity
$27.6M
Debt
$50M
Series A (2019): $22M, investors not publicly disclosed
Series C (2022): $38.5M led by MVM Partners
Private Equity (2024): $27.6M supported by OCV Partners, Questa Capital, Courage Capital Management, and MVM Partners
Debt (2026): $50M featuring Monroe Capital and Horizon Technology Finance
Key Investors in OSSIO
Monroe Capital
Monroe Capital is a private credit asset management firm specializing in providing financing solutions to middle-market companies across various industries, focusing on direct lending and customized capital structures.
Horizon Technology Finance
Horizon Technology Finance is a specialty finance company that provides structured debt financing solutions to development-stage companies, particularly in the technology and life sciences sectors.
MVM Partners
MVM Partners LLP invests in innovative healthcare companies, actively supporting businesses that enhance healthcare delivery through quality and cost-effective solutions in medical technology and digital health.
What's next for OSSIO?
With the recent influx of capital, OSSIO is poised to deepen its market penetration and expand its product portfolio within the orthopedic surgery space. The strategic focus will likely shift toward scaling manufacturing capabilities and broadening clinical evidence to support the widespread adoption of OSSIOfiber across global healthcare systems. As the company matures, the integration of this latest financing will be instrumental in navigating the complexities of large-scale medical device commercialization, ensuring that OSSIO remains at the forefront of regenerative orthopedic medicine while maintaining its competitive edge against traditional implant manufacturers.
See full OSSIO company page
